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Abstract: Background and purpose 
Image-guided radiotherapy (IGRT) improves treatment set-up accuracy and 
provides the opportunity to reduce target volume margins. We introduced 
IGRT methods using standard (IGRT-S) or reduced (IGRT-R) margins in a 
randomised phase 2 substudy within CHHiP trial. We present a pre-planned 
analysis of the impact of IGRT on dosimetry and acute/late pelvic side 
effects using gastrointestinal and genitourinary clinician and patient-
reported outcomes (PRO) and evaluate efficacy. 
 
Materials and methods 
CHHiP is a randomised phase 3, non-inferiority trial for men with 
localised prostate cancer. 3216 patients were randomly assigned to 
conventional (74Gy in 2Gy/fraction (f) daily) or moderate 
hypofractionation (60 or 57Gy in 3Gy/f daily) between October 2002 and 
June 2011.  The IGRT substudy included a second randomisation assigning 
to no-IGRT, IGRT-S (standard CTV-PTV margins), or IGRT-R (reduced CTV-PTV 
margins). Primary substudy endpoint was late RTOG bowel and urinary 
toxicity at 2 years post-radiotherapy.  
 
Results 
Between June 2010 to July 2011, 293 men were recruited from 16 centres. 
Median follow-up is 56.9(IQR 54.3-60.9)months. Rectal and bladder dose-
volume and surface percentages were significantly lower in IGRT-R 
compared to IGRT-S group;(p<0.0001). Cumulative proportion with RTOG 
grade>2 toxicity reported to 2 years for bowel was 8.3(95% CI 3.2-20.7)%, 
8.3(4.7-14.6)% and 5.8(2.6-12.4)% and for urinary 8.4(3.2-20.8)%, 
4.6(2.1-9.9)% and 3.9(1.5-9.9)% in no IGRT, IGRT-S and IGRT-R groups 
respectively. In an exploratory analysis, treatment efficacy appeared 
similar in all three groups.  
 
Conclusion 
Introduction of IGRT was feasible in a national randomised trial and 
IGRT-R produced dosimetric benefits. Overall side effect profiles were 
acceptable in all groups but lowest with IGRT and reduced margins. 
 
Research Data Related to this Submission 
-------------------------------------------------- 
There are no linked research data sets for this submission. The following 
reason is given: 
Data may only be released through completion of an ICR-CTSU data access 
form, approval of the CHHiP Trial Management Group (TMG) and Trial 
Steering Committee (TSC) and signed data sharing agreement. 
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Dear Professor Baumann, 
 
 
RE: Revision of manuscript: A randomised assessment of image 
guided radiotherapy within a phase 3 trial of Conventional or  
Hypofractionated High Dose Intensity Modulated Radiotherapy  
for Prostate Cancer (CHHiP) 
 
 
Many thanks for allowing us to address the reviewers’ comments, please 
find below our responses in italic text and revisions noted within the 
manuscript. 
  
 
Reviewer #1: This is a nicely conducted substudy of the CHHiP trial which 
seeks to determine whether IGRT reduces rectal and urinary toxicity after 
two years of follow up.  This report convincingly shows that IGRT 
achieved this. 
 
This was not a surprise for this reviewer because gold grain guided IGRT with insertion by 
a local urologist quickly demonstrated that IGRT reduced rectal and urinary toxicity at my 
centre.  In fact, the better we became at using gold grains, the less our rectal and urinary 
toxicity became.  We also sent a report of our experience to the Red Journal. 
 
We agree with the reviewer and think it is important for these modern radiotherapy 
techniques to be reported and robustly evaluated. 
 
 
Reviewer #3: Authors should be commended for their effort in conducting this substudy. 
The paper is well written, sound and the MM or Results sections do not require 
modifications.  
 
Professor Michael Baumann 
Editor-in-Chief, Radiotherapy and Oncology 
 
23rd October 2019 
 
 
*Point by Point detailed Response to Reviewer comments
However I have two major concerns: 
1. regarding application of the findings, most guidelines now mandate daily IGRT so this 
trial will likely not affect the guidelines 
 
Currently, NHS England guidelines for hypofractionated radiotherapy (60Gy/20F) mandate 
intensity modulated radiotherapy techniques with strict normal tissue dose constraints and 
recommend image guidance techniques. The use of IGRT is also recommended within 
the ASTRO/ASCO/AUA guideline for hypofractionated prostate radiotherapy. In addition, 
this study also evaluates the effect of a reduced PTV margin with image guidance.  
 
2. more importantly, the authors claim that this is the first IGRT trial published so far, when 
in reality, to my knowledge, there are at least TWO randomized trials already published 
(de Crevoisier et al, IJROBP 2018 and Tondel et al, Radiother Oncol 2018) that the 
authors should discuss. Hence the discussion should be re-written to compare their 
findings with the ones from the other trials, which are different in many ways. 
 
We have amended and clarified the sentence concerning this study in relation to other 
prostate IGRT trials, and it now reads ‘To our knowledge, this is the only randomised 
study undertaken evaluating daily prostate image-guided IMRT with and without reduced 
PTV margins’ (last sentence of Introduction). We are grateful to the reviewer for 
highlighting these trials and have included these studies within the discussion. These 
studies both showed no difference in clinician or patient reported acute toxicity between 
daily and weekly IGRT, with de Crevoisier study showing an improvement in biochemical 
progression and late rectal toxicity with daily IGRT. This study also cautiously suggested 
that there might be an increase in the incidence of 2nd cancers in the daily group and this 
will be reviewed in due course within the CHHiP study. 
 
 
Reviewer #4: well written manuscript of a well conceived and well executed clinical trial. 
I had difficulty finding the exact normal tissue constraints and dose planning objectives 
despite the references given.  please include a table of the normal tissue constraints 
utilized for the trial. 
Was there central review of the treatment volumes and normal tissue volumes for patients 
enrolled? 
Did all patients enrolled in the trial meet the dose constraints stipulated in the study? 
 
Thank you to the reviewer for their comments. We agree that it is important for dose 
constraints to be available for readers and we have expanded Table S2 to include the 
normal tissue dose constraints for the 3Gy per fraction schedules. 
 
Regarding the comment on quality assurance and central review of volumes, we did not 
have the personnel to review all outlining centrally. However, all centres underwent 
prospective case reviews of clinical outlining by the chief investigator for the first two 
patients recruited per centre. An additional moderate-risk case was reviewed if the first 
two patients were low risk, and extra reviews were requested if significant errors 
persisted. Our quality assurance methods for CHHiP including this detail has been 
recently published and is now referenced within the manuscript (Naismith O, Mayles H. et 
al. Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus 
Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer. 
Clinical Oncology 2019: 31: 611-620).  
 
We are grateful for the question concerning the proportion of patients meeting the dose 
constraints within the study. We have included this information relating to rectum, bowel 
and bladder dose constraints as a statement within the results section, with further details 
in the supplementary information.  
 
Editorial Office Comments: 
- Please provide the Clinical Trial number below the abstract. 
- The subheading "Conclusions" should be removed. 
 
We have included the clinical trial number and removed the subheadings within the results 
section and removed the conclusions subheading.  
 
If there are any questions, please do not hesitate to contact me. 
 
Yours sincerely, 
 
 
 
 
Prof David Dearnaley 
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Abstract  
Background and purpose 
Image-guided radiotherapy (IGRT) improves treatment set-up accuracy and provides 
the opportunity to reduce target volume margins. We introduced IGRT methods 
using standard (IGRT-S) or reduced (IGRT-R) margins in a randomised phase 2 
substudy within CHHiP trial. We present a pre-planned analysis of the impact of 
IGRT on dosimetry and acute/late pelvic side effects using gastrointestinal and 
genitourinary clinician and patient-reported outcomes (PRO) and evaluate efficacy. 
 
Materials and methods 
CHHiP is a randomised phase 3, non-inferiority trial for men with localised prostate 
cancer. 3216 patients were randomly assigned to conventional (74Gy in 2Gy/fraction 
(f) daily) or moderate hypofractionation (60 or 57Gy in 3Gy/f daily) between October 
2002 and June 2011.  The IGRT substudy included a second randomisation 
assigning to no-IGRT, IGRT-S (standard CTV-PTV margins), or IGRT-R (reduced 
CTV-PTV margins). Primary substudy endpoint was late RTOG bowel and urinary 
toxicity at 2 years post-radiotherapy.  
 
Results 
Between June 2010 to July 2011, 293 men were recruited from 16 centres. Median 
follow-up is 56.9(IQR 54.3-60.9)months. Rectal and bladder dose-volume and 
surface percentages were significantly lower in IGRT-R compared to IGRT-S 
group;(p<0.0001). Cumulative proportion with RTOG grade>2 toxicity reported to 2 
years for bowel was 8.3(95% CI 3.2-20.7)%, 8.3(4.7-14.6)% and 5.8(2.6-12.4)% and 
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 5 
for urinary 8.4(3.2-20.8)%, 4.6(2.1-9.9)% and 3.9(1.5-9.9)% in no IGRT, IGRT-S and 
IGRT-R groups respectively. In an exploratory analysis, treatment efficacy appeared 
similar in all three groups.  
 
Conclusion 
Introduction of IGRT was feasible in a national randomised trial and IGRT-R 
produced dosimetric benefits. Overall side effect profiles were acceptable in all 
groups but lowest with IGRT and reduced margins. 
 
ISRCTN: 97182923 
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Introduction  
Intensity-modulated radiotherapy (IMRT) enables dose escalation to the prostate 
target volume, with low gastrointestinal or genitourinary toxicity.1–4 The success of 
radical prostate radiotherapy depends on accurate delivery of high dose conformal 
radiotherapy to a defined target volume. Image guided radiotherapy (IGRT) with daily 
online imaging has the potential to improve prostate localisation, consequently 
improving treatment accuracy and reducing the required clinical (CTV) to planning 
(PTV) target volume margin.5 This may reduce the amount of normal tissue receiving 
target doses, and consequently toxicity.6 Intrafraction motion and outlining 
uncertainties still necessitate a small margin around the CTV.5  
 
In addition to optimising prostate radiotherapy techniques, there has been interest in 
the exploitation of fraction sensitivity of prostate cancer through hypofractionation.7–9 
This has been successfully examined within the UK multicentre randomised 
controlled trial (Conventional or Hypofractionated High-dose Intensity Modulated 
Radiotherapy in Prostate Cancer; CHHiP) which aimed to compare the efficacy and 
toxicity of conventional and hypofractionated radiotherapy using high-quality 
radiation techniques. Within the trial, 3216 patients were enrolled from 71 centres 
within the UK between October 2002 and June 2011.10  
 
During the latter stages of the CHHiP trial, IGRT became available in participating 
treatment centres. To assess this technology the CHHiP IGRT phase 2 substudy 
was developed. We aimed to determine the feasibility and generalisability of IGRT in 
the context of a multicentre trial and assess acute and late toxicity. A patient 
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 7 
reported outcome (PRO) protocol was subsequently integrated into the substudy. To 
our knowledge, this is the only randomised study undertaken evaluating daily 
prostate image-guided IMRT with and without reduced PTV margins.  
 
 
Materials and Methods  
 
Study design and participants 
CHHiP is a randomised phase 3, non-inferiority trial which recruited men with 
localised prostate cancer (pT1b-T3aN0M0).10 Patients were randomly assigned 
(1:1:1) to conventional 74 Gray (Gy) in 2Gy/fraction (f) daily or one of two 
hypofractionated schedules giving 60Gy or 57Gy in 3Gy/f daily. Patients were all 
treated with IMRT.11  
 
The IGRT substudy was approved by Central London REC1 Research Ethics 
Committee (10/H0718/31) and implemented in June 2010. Men who had entered the 
CHHiP trial were eligible for the IGRT substudy with additional consent and provided 
they had no contraindication to implanted fiducial markers or a hip prosthesis or 
fixation which would interfere with positional imaging. Following dose/fractionation 
randomisation in the main CHHiP trial, minimisation was used to assign IGRT 
substudy patients in a 1:1:1 ratio to either no-IGRT – using standard CHHiP planning 
margins, IGRT using standard CHHiP planning margins (IGRT-S), or IGRT with 
reduced planning margins (IGRT-R). Radiotherapy centre and dose/fractionation 
schedule were used as balancing factors. Neither patients nor clinicians were 
blinded to allocation. Sixteen UK radiotherapy centres took part in the IGRT 
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substudy. Centres could choose, depending on previous IGRT experience, to 
randomise to all three treatment technique options or to the 2-way randomisations: 
no IGRT versus IGRT-S or IGRT-S versus IGRT-R. Four centres used the 3-way 
randomisation, five centres randomised to no-IGRT vs IGRT-S and seven centres 
randomised to IGRT-S vs IGRT-R. In 2014, a patient reported outcomes (PRO) 
assessment was introduced to collect data at a single time point at least three years 
post randomisation. This separate protocol received ethical approval from the NRES 
Committee South West – Central Bristol (14/SW/1071).  
 
Treatment 
Patients randomised to treatment with IGRT, either had fiducial markers inserted into 
the prostate using trans-rectal ultrasound guidance or soft tissue matching if using 
the TomoTherapy® system. Fiducial markers were implanted with antibiotic cover 
approximately 2 weeks prior to the radiotherapy planning scan. Patient positioning 
was supine and target and treatment planning volumes have been previously 
described.11 Radiotherapy was planned and delivered using an integrated 
simultaneous boost technique (SIB) with three different target volumes and dose 
levels as previously detailed12 and illustrated in Table S1. In the no-IGRT and IGRT-
S arms the standard CHHiP CTV to PTV posterior margins of 10mm/5mm/0mm were 
used. In the IGRT-R arm, these posterior margins were 6mm/3mm/0mm. Mandatory 
dose constraints were defined for both target coverage and avoidance of normal 
tissues including rectum, bowel, bladder and femoral heads (Table S2). Treatment 
was delivered with 6-15 MV photons with multileaf collimators to shape beams. 
Patients randomised to no-IGRT had offline portal imaging to verify treatment 
accuracy; the match to bony landmarks was to be within 3mm.  Patients receiving 
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 9 
IGRT had daily pre-treatment imaging and any observed set-up error >2mm was 
corrected prior to treatment. No post-correction imaging was taken. A prospective 
quality-assurance programme was designed as an integral part of the study13 
including specific aspects for the IGRT substudy (Supplementary material).  
 
Trial assessments 
Pre-trial staging investigations included PSA, lymph node assessment by MRI or CT, 
and bone scan. Histology was assessed from diagnostic TRUS guided biopsies (or 
TURP specimens) and reported using the Gleason system.  
Toxicity experienced from fiducial marker insertion was recorded using CTCAE 
grading.14 
Pre-hormone and pre-radiotherapy clinical assessments used Late Effects of Normal 
Tissues Subjective-Objective Management (LENT-SOM)15 and the Royal Marsden 
Hospital (RMH) grading.16 Clinical assessment of acute toxicity was made weekly 
during radiotherapy and at weeks 10, 12 and 18 from the start of radiotherapy using 
the Radiation Therapy Oncology Group (RTOG) scoring system.17 Late toxicity was 
assessed at 6, 12, 18 and 24 months then annually to 5 years using RTOG, 
LENTSOM and RMH scoring systems.  
In the PRO substudy, data was collected at a single time point using the Expanded 
Prostate Cancer Index Composite (EPIC) questionnaire, (EPIC-50 used for bowel 
and urinary domains and EPIC-26 for sexual and hormonal domains),18 the Vaizey 
Incontinence,19 Short Form 12 (SF-12)20 and International Index of Erectile Function 
(IIEF-5)21 questionnaires. Questionnaires were sent directly from participating 
centres to patients (following confirmation of health status) who were at least three 
years from completing treatment. A single reminder letter was sent.  
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For each patient, treatment planning data (planning CT, dose distribution and organ 
contours) were uploaded using dedicated analysis software (VODCA. MSS Medical 
Software Solutions, Hagendorn, Switzerland). Using in-house code, all radiotherapy 
plans were converted into equivalent dose in 2Gy per fraction, using Withers 
formula22 with an / ratio of 3Gy for rectum and 5Gy for bladder for each dose cube 
voxel. Dose volume (DVH) and dose-surface (DSH) histograms were generated for 
rectum and bladder.  
 
Statistical considerations 
The IGRT substudy was non-comparative and powered to assess toxicity 
independently within each treatment technique group using Simon single stage 
design with exact p-values.23 The primary endpoint was proportion of patients with 
RTOG bladder or bowel toxicity of grade >2 at two years from starting radiotherapy. 
Secondary endpoints included acute toxicity, prevalence of late radiation induced 
toxicity, time to late radiation induced toxicity, toxicity associated with fiducials and 
feasibility of delivery of IGRT in a multi-centre setting. Efficacy has been included as 
exploratory analyses. Ninety-one patients were required (with 79 or more remaining 
toxicity-free) in each group to give 80% power to detect a 10% RTOG bladder/bowel 
grade >2 toxicity rate at 2 years with IGRT assuming a 20% toxicity rate with no 
IGRT (alpha 3.4%). Sample size was not calculated for the PRO substudy, all 
eligible IGRT substudy patients were invited to participate.  
 
Analysis methods 
All analyses have been presented according to randomly allocated treatment 
technique group. Analyses of side effects included all data available at each time 
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point for patients who received at least one fraction of radiotherapy (unless otherwise 
stated).  Worst acute bladder and bowel toxicity was calculated using worst grade 
reported during the first 18 weeks from start of radiotherapy. For the primary 
endpoint, only patients with a 2-year RTOG toxicity assessment were included in the 
denominator, although a sensitivity analysis was conducted using all randomised 
patients. The proportion of patients with RTOG bladder or bowel toxicity of grade ≥2 
at 2 years were presented together with exact binomial 95% confidence intervals. 
Time to first occurrence of late radiation induced side effects were analysed using 
Kaplan Meier method to calculate the cumulative proportion with events reported on 
2-year assessment form for each scoring system. Time was measured from start of 
radiotherapy. Patients not experiencing an event were censored at date of last 
toxicity assessment or at date of death for deceased patients. The log-rank test was 
used to compare no IGRT versus IGRT-S and IGRT-S versus IGRT-R with a 
significance level of 1%, to account for multiple comparisons. Biochemical/clinical 
failure was defined as time to first PSA failure (PSA value greater than nadir +2ng/ml 
with a consecutive confirmatory PSA value) or prostate cancer recurrence (local, 
lymph node, pelvic or distant). Patients event free at the time of analysis were 
censored at their last know PSA assessment. 
 
Statistical analyses were based on a data snapshot taken on 18th May 2016 (except 
for efficacy analyses which were based on a snapshot taken on 3rd April 2018 to 
maximise data maturity). All analyses were performed using STATA Version 13.1. 
Patient reported outcomes were scored in accordance with the recommended 
scoring manuals24,25 and presented as descriptive statistics by treatment group.  The 
Vaizey questionnaire is scored on a continuous scale, with minimum score, 0 
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representing perfect continence and a maximum score, 24 representing total 
incontinence.19 Patients were divided into 3 categories for Vaizey total score 
according to tertiles and dose data presented. In health related quality of life, the 
clinically meaningful change is defined as a mean change score exceeding half the 
standard deviation of  baseline value.26 As there was no baseline data available for 
this patient group, the mean and standard deviation values from the main CHHiP trial 
QoL substudy27 (Table S3) were used to define a threshold score for a meaningful 
change for the EPIC bowel and urinary domain scores. 
 
Results  
Two-hundred and ninety-three patients (48 no-IGRT, 137 IGRT-S and 108 IGRT-R) 
from 16 radiotherapy centres across the UK were randomised between July 2010 
and June 2011. Baseline characteristics were balanced between treatment 
technique groups (Table 1) with median age of 71 (IQR 66-74), median pre-hormone 
PSA of 9.5ng/ml (IQR 6.8-12.40) and 12%, 77% and 11% low, intermediate and high 
risk respectively. At the time of the data snapshot for toxicity, median follow-up was 
56.9 months (IQR 54.3-60.9) and for efficacy 73.3 (IQR 64.9-74.6) months.  
 
Three patients received no radiotherapy (one withdrew consent, one died and one 
biochemically progressed prior to radiotherapy). Adherence to randomly allocated 
treatment technique was high (Figure 1): three no-IGRT patients received IGRT, nine 
IGRT-S patients did not receive standard CHHiP planning margins and four IGRT-R 
patients did not have reduced margins. Two-hundred and twenty-five patients had 
image guidance using fiducials, 11 patients were treated using TomoTherapy® and 
six patients using CT on rails. 
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Median (IQR) rectum volumes were 65 (59-77), 68 (56-86) and 67 (58-85) cm3 for 
the no-IGRT, IGRT-S and IGRT-R groups respectively. Corresponding figures for 
bladder volumes were 277 (200-379), 249 (167-375) and 281 (180-386) cm3 (Table 
S4). A summary of DVH and DSH for rectum and bladder by treatment group are 
shown in Figure 2. Both rectal and bladder dose volume and surface percentages 
were consistently statistically lower in the IGRT-R compared to IGRT-S group (Table 
S5). Adherence to rectal dose constraints of 68% to 100% of prescribed dose and 
the bowel constraint was seen for 98% of patients, with all patients within the IGRT-
R group achieving all these constraints (Table S6-S7).  
 
Toxicity associated with fiducial marker insertion was minimal with 19/190 (10%) 
reporting grade 1 and one patient reporting grade 2 haemorrhage. Six (3%) patients 
had an infection, three grade 1, two grade 2 and one grade 3. Worst RTOG bowel 
toxicity reported during 18 weeks from starting radiotherapy was grade ≥2 in 13/48 
(27%), 38/135 (28%) and 26/107 (24%) of no-IGRT, IGRT-S and IGRT-R patients 
respectively. Corresponding figures for RTOG bladder grade ≥2 were 21/48 (44%), 
71/135 (53%) and 48/107 (45%). By week 18, majority of toxicity had resolved with 
grade≥2 bowel toxicity reported in 0% no-IGRT, 5% IGRT-S and 2% IGRT-R 
patients and RTOG bladder grade ≥2 reported in 3% no-IGRT, 8% IGRT-S and 4% 
IGRT-R patients (Figure 3). 
 
At two years, RTOG bowel and bladder toxicity was low across all treatment 
technique groups (Table S6) with 13 out of 274 (4.7%) patients assessed reporting 
any RTOG grade ≥2 toxicity, which was the primary endpoint of the substudy. The 
upper limits of 95% confidence intervals ruled out greater than 20% toxicity within 
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each treatment technique group. Moderate to severe RTOG bowel toxicity was 
similar across treatment groups, with 1/46 (2%), 3/125 (2%) and 2/103 (2%) no-
IGRT, IGRT-S and IGRT-R patients reporting grade ≥2 at 2 years. Cumulative 
proportion with grade ≥2 RTOG bowel toxicity reported to 2 years was 8.3% (95%CI 
3.2-20.7), 8.3% (4.7-14.6%) and 5.8% (2.6-12.4%) for no-IGRT, IGRT-S and IGRT-R 
groups respectively (Figure 4A and Table S8).  RMH and LENTSOM scales showed 
similar low levels of moderate to severe bowel/rectum toxicity. RMH bowel grade ≥2 
showed reduced toxicity in the IGRT-R group compared to IGRT-S with borderline 
statistical significance (HR=0.39, 95%CI 0.18-0.83, p=0.012).  
 
Moderate to severe RTOG bladder toxicity was similar across treatment technique 
groups, with 1/46 (2%), 4/125 (3%) and 2/103 (2%) no-IGRT, IGRT-S and IGRT-R 
patients reporting grade ≥2 at 2 years. Cumulative proportion of RTOG bladder 
grade ≥2 toxicity by 2 years was low for all groups with the least toxicity reported in 
the IGRT-R group: 8.4 (3.2-20.8)%, 4.6 (2.1-9.9)% and 3.9 (1.5-9.9)% for no-IGRT, 
IGRT-S and IGRT-R groups respectively (Figure 4B and Table S9). The RMH and 
LENTSOM scales reported higher incidences of bladder toxicity compared to RTOG 
but with a similar trend across groups. There was no evidence of significant 
differences between treatment technique groups. 
 
A total of 193/265 (72.8%) PRO booklets were completed at a median of 50.3 
months (IQR 47.8-52.0) from randomisation. Baseline characteristics were balanced 
between treatment technique groups and there were no significant differences 
between patients who did and did not complete the PRO booklet (Table S10). There 
was no evidence of any differences between treatment technique groups for EPIC or 
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Vaizey summary scores (Table 2), with no suggestion of a worsening of Vaizey 
score with increased dose volume or dose surface at any dose level (Table S11). 
Median DVH and DSH values were calculated for patients whose EPIC bowel and 
urinary scores were below and above the threshold level previously defined (Table 
S3). There was a trend that patients whose score were below the cut-point had 
higher dose volume or surface levels (Figure S1).  
 
Thirty-three patients had biochemical/clinical failure reported (4, 20 and 9 in no 
IGRT, IGRT-S and IGRT-R groups respectively) (Table S12 and Figure S2). Five-
year biochemical/clinical failure free survival was 91.1 (95% CI 77.9-96.6), 85.2 
(95%CI 77.7-90.3) and 93.1 (95%CI 86.1-96.7) for no IGRT, IGRT-S and IGRT-R 
groups respectively. Fourteen patients had recommenced androgen deprivation 
therapy, nine had local recurrence, seven had lymph node/pelvic recurrence and 
seven had distant recurrence. Twenty-seven patients had died, three from prostate 
cancer, twenty-three from other reasons and one unknown.  
 
Discussion  
We have demonstrated that implementation of IGRT was feasible in a multi-centre 
trial in the UK. Recruitment of patients was swift and completed within one year. 
Accrual peaked at 45 patient/month, with 16 radiotherapy centres participating. 
Subsequently IGRT has become part of the national guidelines recommended 
treatment pathway. This emphasises the importance of clinical trials as a vehicle to 
introduce advanced radiotherapy technology. Limitations of this substudy include its 
relatively small size, uneven randomisation between treatment technique groups and 
PRO assessment at a single time point. Yet, to our knowledge, this is the only 
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randomised prospective study evaluating no-IGRT, IGRT and treatment margins 
using the same planning techniques. 
We found minimal toxicity associated with insertion of fiducial markers. Dosimetric 
assessments showed that reduced margins in the IGRT-R group resulted in rectal 
and bladder volumes receiving 5-65Gy being significantly lower (<0.0001) than using 
standard margins, this was also seen for surface dose. The mean dose to rectal 
surface in the IGRT-S group was  33.9(±5.1)Gy and similar to that previously 
reported of 34.4(±7.2)Gy using IG-IMRT28 despite differences in dose prescription 
and margining techniques. As expected, mean dose to rectum in the IGRT-R group 
was significantly lower at 28.9(±4.2)Gy. Similarly, mean dose to bladder surface was 
26.6(±9.2)Gy / 20.5(±6.6)Gy for IGRT-S / IGRT-R groups respectively, both lower 
than previously reported (33.1 ± 10.9Gy).28 Late GI toxicity was consistently reported 
less often using the three clinician based scores in the IGRT-R group. However, the 
improved rectal dosimetry did not translate into a statistically significant benefit in 
acute or late GI toxicity, with the possible exception of grade ≥2 RMH GI side-effects. 
This perhaps unexpected result may relate to the low level of side-effects seen in all 
randomised dose/fractionation groups in the main CHHiP trial which used strict 
normal tissue dose constraints and a SIB technique limiting dose to the seminal 
vesicles.10 The lack of reduction in acute and late GU side effects may relate to 
similar doses to the urethra in all treatment technique groups. It may be the 
combination of dose/volume/fractionation employed in the trial has reached a plateau 
for radiotherapy side effects and other patient29, radiogenomic30 or microbiota31 
related factors become more important in determining residual symptoms. We 
believe it imprudent to extrapolate to treatments using higher doses, treating larger 
target volumes or using more extreme forms of hypofractionation where the clinical 
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benefits of IGRT-R might be more apparent. Previous non-randomised studies 
comparing patient cohorts treated with IG-IMRT and 3D-CFRT28,29 have suggested 
improvements in grade≥2 GU or GI side-effects using IGRT but are compromised by 
differences in planning and delivery techniques as well as differing dose constraints. 
Two randomised trials have evaluated daily versus weekly image guided 
radiotherapy. Tondel et al. reported no difference in acute patient reported 
outcomes, despite dosimetric advantages seen with daily CBCT and reduced 
margins, their late toxicity results are awaited.32 A further study by de Crevoisier et 
al. showed no statistically significant difference in recurrence free survival, with also 
no difference in acute toxicity.33 A statistically significant difference in late rectal 
toxicity and improvement in biochemical recurrence was reported, albeit with a short 
median follow up of 4.1 years. We found no evidence to suggest that IGRT was 
associated with a reduction in disease control. IGRT may increase accuracy and 
reduce the chance of underdosage in the target volume, alternatively however it is 
possible that the reduced margins might lower inadvertent dose outside the prostate 
which has been suggested as a cause of treatment failure.34  
The IGRT experience gained within this study has facilitated development of a new 
national trial PIVOTALboost (CRUK/16/018) in which all patients receive IG-IMRT 
and are randomised to receive pelvic lymph node IMRT or MR-directed dominant 
lesion boosts using hypofractionated schedules as in the CHHiP study. 
 
We have shown it is feasible to introduce prostate IGRT in a national randomised 
trial and that reduced margins translate into dosimetric benefits. Overall side effect 
profiles were low with and without IGRT in the CHHiP trial and this substudy.  
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Figure legends 
Figure 1: CONSORT diagram 
Figure 2: Boxplots illustrating dose volume and dose surface histograms, the 
calculated volume and surface percentages for rectum (A) and bladder (B) normal 
tissues by IGRT group and dose 
KEY: All doses are equivalent dose in 2Gy fractions. Red boxplots represent patients 
treated with no IGRT, green boxplots are those patients treated with IGRT standard 
margins and blue boxplots are those patients treated with IGRT reduced margins. 
Figure 3 – Acute RTOG bowel (A) and bladder (B) toxicity by timepoint and IGRT 
group. Distribution of grade and prevalence 
Figure 4 – Bowel (A) and bladder (B) toxicity assessed using RTOG, RMH and 
LENTSOM by timepoint and IGRT group. Distribution and cumulative proportion with 
grade≥1 and grade≥2 radiation induced late toxicity. 
KEY: For cumulative proportion plots: red=No IGRT, Green= IGRT-S, Blue=IGRT-R. 
Solid lines indicated grade≥1 events and dashed lines indicate grade≥2 events 
NB. Late toxicity data have been included in stacked bar charts if they were reported 
within 6 weeks of the 6 month visit, within 3 months of the 12-24 month visits and 
within 6 months of the 36 and 48 month visits.  
 
Table 1: Baseline characteristics by treatment group (n=293) 
Table 2: Bowel and urinary domain scores using EPIC questionnaire and scoring 
system by treatment group at a median follow-up of 50.3 months (IQR: 47.8-52.0 
months) 
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Supplementary material (online only) 
Table S1: Margin definition and target isodose levels prescriptive to the planning 
Table S2: Normal tissue dose constraints 
Table S3: EPIC bowel domain mean and standard deviation scores from the CHHiP 
QoL substudy and the calculated threshold dose 
Table S4: Treatment planning data 
Table S5: P-values for statistical comparison of dose volume and dose surface 
histograms for No IGRT vs IGRT-S and IGRT-S vs IGRT-R. All doses are in 
equivalent dose in 2Gy fractions. 
Table S6: Descriptive statistics given by IGRT treatment allocation for the rectum 
constraints 
Table S7: Descriptive statistics given by IGRT treatment allocation for the bladder 
constraints 
Table S8: Number and proportion with RTOG grade>=2 toxicity at 2 years with 95% 
confidence intervals - by treatment group and randomisation strategy 
Table S9: Hazard ratios and cumulative proportion with G1+, G2+ and G3+ bowel 
and bladder toxicity at 2 years assessed by RTOG, RMH and LENTSOM scoring 
systems 
Table S10: Baseline characteristics for PRO responders and non-responders 
Table S11: Percentage volume and surface receiving each dose level according to 
Vaizey scores categorised as tertiles (Ter1=Vaizey score 0-2; Ter2=Vaizey total 3-5; 
Ter3=Vaizey score 6-20). All doses are equivalent dose in 2Gy fractions. 
Table S12: Efficacy data by IGRT substudy group 
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Figure S1: Boxplots showing along the top row the dose volume histograms for 
patients whose EPIC bowel (A) and urinary (B) domain scores were above or below 
the defined thresholds. The dose surface histograms are shown along the bottom 
row for those patients whose EPIC bowel (A) and urinary (B) domain scores were 
above or below the defined thresholds. All doses are equivalent dose in 2Gy 
fractions. 
Figure S2: Kaplan Meier for biochemical/clinical failure free survival by IGRT 
substudy group  
Radiotherapy Quality Assurance in the CHHiP IGRT substudy 
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Abstract  
Background and purpose 
Image-guided radiotherapy (IGRT) improves treatment set-up accuracy and provides 
the opportunity to reduce target volume margins. We introduced IGRT methods 
using standard (IGRT-S) or reduced (IGRT-R) margins in a randomised phase 2 
substudy within CHHiP trial. We present a pre-planned analysis of the impact of 
IGRT on dosimetry and acute/late pelvic side effects using gastrointestinal and 
genitourinary clinician and patient-reported outcomes (PRO) and evaluate efficacy. 
 
Materials and methods 
CHHiP is a randomised phase 3, non-inferiority trial for men with localised prostate 
cancer. 3216 patients were randomly assigned to conventional (74Gy in 2Gy/fraction 
(f) daily) or moderate hypofractionation (60 or 57Gy in 3Gy/f daily) between October 
2002 and June 2011.  The IGRT substudy included a second randomisation 
assigning to no-IGRT, IGRT-S (standard CTV-PTV margins), or IGRT-R (reduced 
CTV-PTV margins). Primary substudy endpoint was late RTOG bowel and urinary 
toxicity at 2 years post-radiotherapy.  
 
Results 
Between June 2010 to July 2011, 293 men were recruited from 16 centres. Median 
follow-up is 56.9(IQR 54.3-60.9)months. Rectal and bladder dose-volume and 
surface percentages were significantly lower in IGRT-R compared to IGRT-S 
group;(p<0.0001). Cumulative proportion with RTOG grade>2 toxicity reported to 2 
years for bowel was 8.3(95% CI 3.2-20.7)%, 8.3(4.7-14.6)% and 5.8(2.6-12.4)% and 
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 5 
for urinary 8.4(3.2-20.8)%, 4.6(2.1-9.9)% and 3.9(1.5-9.9)% in no IGRT, IGRT-S and 
IGRT-R groups respectively. In an exploratory analysis, treatment efficacy appeared 
similar in all three groups.  
 
Conclusion 
Introduction of IGRT was feasible in a national randomised trial and IGRT-R 
produced dosimetric benefits. Overall side effect profiles were acceptable in all 
groups but lowest with IGRT and reduced margins. 
 
ISRCTN: 97182923 
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Introduction  
Intensity-modulated radiotherapy (IMRT) enables dose escalation to the prostate 
target volume, with low gastrointestinal or genitourinary toxicity.1–4 The success of 
radical prostate radiotherapy depends on accurate delivery of high dose conformal 
radiotherapy to a defined target volume. Image guided radiotherapy (IGRT) with daily 
online imaging has the potential to improve prostate localisation, consequently 
improving treatment accuracy and reducing the required clinical (CTV) to planning 
(PTV) target volume margin.5 This may reduce the amount of normal tissue receiving 
target doses, and consequently toxicity.6 Intrafraction motion and outlining 
uncertainties still necessitate a small margin around the CTV.5  
 
In addition to optimising prostate radiotherapy techniques, there has been interest in 
the exploitation of fraction sensitivity of prostate cancer through hypofractionation.7–9 
This has been successfully examined within the UK multicentre randomised 
controlled trial (Conventional or Hypofractionated High-dose Intensity Modulated 
Radiotherapy in Prostate Cancer; CHHiP) which aimed to compare the efficacy and 
toxicity of conventional and hypofractionated radiotherapy using high-quality 
radiation techniques. Within the trial, 3216 patients were enrolled from 71 centres 
within the UK between October 2002 and June 2011.10  
 
During the latter stages of the CHHiP trial, IGRT became available in participating 
treatment centres. To assess this technology the CHHiP IGRT phase 2 substudy 
was developed. We aimed to determine the feasibility and generalisability of IGRT in 
the context of a multicentre trial and assess acute and late toxicity. A patient 
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 7 
reported outcome (PRO) protocol was subsequently integrated into the substudy. To 
our knowledge, this is the only randomised study undertaken evaluating daily 
prostate image-guided IMRT with and without reduced PTV margins.  
 
 
Materials and Methods  
 
Study design and participants 
CHHiP is a randomised phase 3, non-inferiority trial which recruited men with 
localised prostate cancer (pT1b-T3aN0M0).10 Patients were randomly assigned 
(1:1:1) to conventional 74 Gray (Gy) in 2Gy/fraction (f) daily or one of two 
hypofractionated schedules giving 60Gy or 57Gy in 3Gy/f daily. Patients were all 
treated with IMRT.11  
 
The IGRT substudy was approved by Central London REC1 Research Ethics 
Committee (10/H0718/31) and implemented in June 2010. Men who had entered the 
CHHiP trial were eligible for the IGRT substudy with additional consent and provided 
they had no contraindication to implanted fiducial markers or a hip prosthesis or 
fixation which would interfere with positional imaging. Following dose/fractionation 
randomisation in the main CHHiP trial, minimisation was used to assign IGRT 
substudy patients in a 1:1:1 ratio to either no-IGRT – using standard CHHiP planning 
margins, IGRT using standard CHHiP planning margins (IGRT-S), or IGRT with 
reduced planning margins (IGRT-R). Radiotherapy centre and dose/fractionation 
schedule were used as balancing factors. Neither patients nor clinicians were 
blinded to allocation. Sixteen UK radiotherapy centres took part in the IGRT 
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 8 
substudy. Centres could choose, depending on previous IGRT experience, to 
randomise to all three treatment technique options or to the 2-way randomisations: 
no IGRT versus IGRT-S or IGRT-S versus IGRT-R. Four centres used the 3-way 
randomisation, five centres randomised to no-IGRT vs IGRT-S and seven centres 
randomised to IGRT-S vs IGRT-R. In 2014, a patient reported outcomes (PRO) 
assessment was introduced to collect data at a single time point at least three years 
post randomisation. This separate protocol received ethical approval from the NRES 
Committee South West – Central Bristol (14/SW/1071).  
 
Treatment 
Patients randomised to treatment with IGRT, either had fiducial markers inserted into 
the prostate using trans-rectal ultrasound guidance or soft tissue matching if using 
the TomoTherapy® system. Fiducial markers were implanted with antibiotic cover 
approximately 2 weeks prior to the radiotherapy planning scan. Patient positioning 
was supine and target and treatment planning volumes have been previously 
described.11 Radiotherapy was planned and delivered using an integrated 
simultaneous boost technique (SIB) with three different target volumes and dose 
levels as previously detailed12 and illustrated in Table S1. In the no-IGRT and IGRT-
S arms the standard CHHiP CTV to PTV posterior margins of 10mm/5mm/0mm were 
used. In the IGRT-R arm, these posterior margins were 6mm/3mm/0mm. Mandatory 
dose constraints were defined for both target coverage and avoidance of normal 
tissues including rectum, bowel, bladder and femoral heads (Table S2). Treatment 
was delivered with 6-15 MV photons with multileaf collimators to shape beams. 
Patients randomised to no-IGRT had offline portal imaging to verify treatment 
accuracy; the match to bony landmarks was to be within 3mm.  Patients receiving 
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IGRT had daily pre-treatment imaging and any observed set-up error >2mm was 
corrected prior to treatment. No post-correction imaging was taken. A prospective 
quality-assurance programme was designed as an integral part of the study13 
including specific aspects for the IGRT substudy (Supplementary material).  
 
Trial assessments 
Pre-trial staging investigations included PSA, lymph node assessment by MRI or CT, 
and bone scan. Histology was assessed from diagnostic TRUS guided biopsies (or 
TURP specimens) and reported using the Gleason system.  
Toxicity experienced from fiducial marker insertion was recorded using CTCAE 
grading.14 
Pre-hormone and pre-radiotherapy clinical assessments used Late Effects of Normal 
Tissues Subjective-Objective Management (LENT-SOM)15 and the Royal Marsden 
Hospital (RMH) grading.16 Clinical assessment of acute toxicity was made weekly 
during radiotherapy and at weeks 10, 12 and 18 from the start of radiotherapy using 
the Radiation Therapy Oncology Group (RTOG) scoring system.17 Late toxicity was 
assessed at 6, 12, 18 and 24 months then annually to 5 years using RTOG, 
LENTSOM and RMH scoring systems.  
In the PRO substudy, data was collected at a single time point using the Expanded 
Prostate Cancer Index Composite (EPIC) questionnaire, (EPIC-50 used for bowel 
and urinary domains and EPIC-26 for sexual and hormonal domains),18 the Vaizey 
Incontinence,19 Short Form 12 (SF-12)20 and International Index of Erectile Function 
(IIEF-5)21 questionnaires. Questionnaires were sent directly from participating 
centres to patients (following confirmation of health status) who were at least three 
years from completing treatment. A single reminder letter was sent.  
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For each patient, treatment planning data (planning CT, dose distribution and organ 
contours) were uploaded using dedicated analysis software (VODCA. MSS Medical 
Software Solutions, Hagendorn, Switzerland). Using in-house code, all radiotherapy 
plans were converted into equivalent dose in 2Gy per fraction, using Withers 
formula22 with an / ratio of 3Gy for rectum and 5Gy for bladder for each dose cube 
voxel. Dose volume (DVH) and dose-surface (DSH) histograms were generated for 
rectum and bladder.  
 
Statistical considerations 
The IGRT substudy was non-comparative and powered to assess toxicity 
independently within each treatment technique group using Simon single stage 
design with exact p-values.23 The primary endpoint was proportion of patients with 
RTOG bladder or bowel toxicity of grade >2 at two years from starting radiotherapy. 
Secondary endpoints included acute toxicity, prevalence of late radiation induced 
toxicity, time to late radiation induced toxicity, toxicity associated with fiducials and 
feasibility of delivery of IGRT in a multi-centre setting. Efficacy has been included as 
exploratory analyses. Ninety-one patients were required (with 79 or more remaining 
toxicity-free) in each group to give 80% power to detect a 10% RTOG bladder/bowel 
grade >2 toxicity rate at 2 years with IGRT assuming a 20% toxicity rate with no 
IGRT (alpha 3.4%). Sample size was not calculated for the PRO substudy, all 
eligible IGRT substudy patients were invited to participate.  
 
Analysis methods 
All analyses have been presented according to randomly allocated treatment 
technique group. Analyses of side effects included all data available at each time 
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point for patients who received at least one fraction of radiotherapy (unless otherwise 
stated).  Worst acute bladder and bowel toxicity was calculated using worst grade 
reported during the first 18 weeks from start of radiotherapy. For the primary 
endpoint, only patients with a 2-year RTOG toxicity assessment were included in the 
denominator, although a sensitivity analysis was conducted using all randomised 
patients. The proportion of patients with RTOG bladder or bowel toxicity of grade ≥2 
at 2 years were presented together with exact binomial 95% confidence intervals. 
Time to first occurrence of late radiation induced side effects were analysed using 
Kaplan Meier method to calculate the cumulative proportion with events reported on 
2-year assessment form for each scoring system. Time was measured from start of 
radiotherapy. Patients not experiencing an event were censored at date of last 
toxicity assessment or at date of death for deceased patients. The log-rank test was 
used to compare no IGRT versus IGRT-S and IGRT-S versus IGRT-R with a 
significance level of 1%, to account for multiple comparisons. Biochemical/clinical 
failure was defined as time to first PSA failure (PSA value greater than nadir +2ng/ml 
with a consecutive confirmatory PSA value) or prostate cancer recurrence (local, 
lymph node, pelvic or distant). Patients event free at the time of analysis were 
censored at their last know PSA assessment. 
 
Statistical analyses were based on a data snapshot taken on 18th May 2016 (except 
for efficacy analyses which were based on a snapshot taken on 3rd April 2018 to 
maximise data maturity). All analyses were performed using STATA Version 13.1. 
Patient reported outcomes were scored in accordance with the recommended 
scoring manuals24,25 and presented as descriptive statistics by treatment group.  The 
Vaizey questionnaire is scored on a continuous scale, with minimum score, 0 
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representing perfect continence and a maximum score, 24 representing total 
incontinence.19 Patients were divided into 3 categories for Vaizey total score 
according to tertiles and dose data presented. In health related quality of life, the 
clinically meaningful change is defined as a mean change score exceeding half the 
standard deviation of  baseline value.26 As there was no baseline data available for 
this patient group, the mean and standard deviation values from the main CHHiP trial 
QoL substudy27 (Table S3) were used to define a threshold score for a meaningful 
change for the EPIC bowel and urinary domain scores. 
 
Results  
Two-hundred and ninety-three patients (48 no-IGRT, 137 IGRT-S and 108 IGRT-R) 
from 16 radiotherapy centres across the UK were randomised between July 2010 
and June 2011. Baseline characteristics were balanced between treatment 
technique groups (Table 1) with median age of 71 (IQR 66-74), median pre-hormone 
PSA of 9.5ng/ml (IQR 6.8-12.40) and 12%, 77% and 11% low, intermediate and high 
risk respectively. At the time of the data snapshot for toxicity, median follow-up was 
56.9 months (IQR 54.3-60.9) and for efficacy 73.3 (IQR 64.9-74.6) months.  
 
Three patients received no radiotherapy (one withdrew consent, one died and one 
biochemically progressed prior to radiotherapy). Adherence to randomly allocated 
treatment technique was high (Figure 1): three no-IGRT patients received IGRT, nine 
IGRT-S patients did not receive standard CHHiP planning margins and four IGRT-R 
patients did not have reduced margins. Two-hundred and twenty-five patients had 
image guidance using fiducials, 11 patients were treated using TomoTherapy® and 
six patients using CT on rails. 
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Median (IQR) rectum volumes were 65 (59-77), 68 (56-86) and 67 (58-85) cm3 for 
the no-IGRT, IGRT-S and IGRT-R groups respectively. Corresponding figures for 
bladder volumes were 277 (200-379), 249 (167-375) and 281 (180-386) cm3 (Table 
S4). A summary of DVH and DSH for rectum and bladder by treatment group are 
shown in Figure 2. Both rectal and bladder dose volume and surface percentages 
were consistently statistically lower in the IGRT-R compared to IGRT-S group (Table 
S5). Adherence to rectal dose constraints of 68% to 100% of prescribed dose and 
the bowel constraint was seen for 98% of patients, with all patients within the IGRT-
R group achieving all these constraints (Table S6-S7).  
 
Toxicity associated with fiducial marker insertion was minimal with 19/190 (10%) 
reporting grade 1 and one patient reporting grade 2 haemorrhage. Six (3%) patients 
had an infection, three grade 1, two grade 2 and one grade 3. Worst RTOG bowel 
toxicity reported during 18 weeks from starting radiotherapy was grade ≥2 in 13/48 
(27%), 38/135 (28%) and 26/107 (24%) of no-IGRT, IGRT-S and IGRT-R patients 
respectively. Corresponding figures for RTOG bladder grade ≥2 were 21/48 (44%), 
71/135 (53%) and 48/107 (45%). By week 18, majority of toxicity had resolved with 
grade≥2 bowel toxicity reported in 0% no-IGRT, 5% IGRT-S and 2% IGRT-R 
patients and RTOG bladder grade ≥2 reported in 3% no-IGRT, 8% IGRT-S and 4% 
IGRT-R patients (Figure 3). 
 
At two years, RTOG bowel and bladder toxicity was low across all treatment 
technique groups (Table S6) with 13 out of 274 (4.7%) patients assessed reporting 
any RTOG grade ≥2 toxicity, which was the primary endpoint of the substudy. The 
upper limits of 95% confidence intervals ruled out greater than 20% toxicity within 
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each treatment technique group. Moderate to severe RTOG bowel toxicity was 
similar across treatment groups, with 1/46 (2%), 3/125 (2%) and 2/103 (2%) no-
IGRT, IGRT-S and IGRT-R patients reporting grade ≥2 at 2 years. Cumulative 
proportion with grade ≥2 RTOG bowel toxicity reported to 2 years was 8.3% (95%CI 
3.2-20.7), 8.3% (4.7-14.6%) and 5.8% (2.6-12.4%) for no-IGRT, IGRT-S and IGRT-R 
groups respectively (Figure 4A and Table S8).  RMH and LENTSOM scales showed 
similar low levels of moderate to severe bowel/rectum toxicity. RMH bowel grade ≥2 
showed reduced toxicity in the IGRT-R group compared to IGRT-S with borderline 
statistical significance (HR=0.39, 95%CI 0.18-0.83, p=0.012).  
 
Moderate to severe RTOG bladder toxicity was similar across treatment technique 
groups, with 1/46 (2%), 4/125 (3%) and 2/103 (2%) no-IGRT, IGRT-S and IGRT-R 
patients reporting grade ≥2 at 2 years. Cumulative proportion of RTOG bladder 
grade ≥2 toxicity by 2 years was low for all groups with the least toxicity reported in 
the IGRT-R group: 8.4 (3.2-20.8)%, 4.6 (2.1-9.9)% and 3.9 (1.5-9.9)% for no-IGRT, 
IGRT-S and IGRT-R groups respectively (Figure 4B and Table S9). The RMH and 
LENTSOM scales reported higher incidences of bladder toxicity compared to RTOG 
but with a similar trend across groups. There was no evidence of significant 
differences between treatment technique groups. 
 
A total of 193/265 (72.8%) PRO booklets were completed at a median of 50.3 
months (IQR 47.8-52.0) from randomisation. Baseline characteristics were balanced 
between treatment technique groups and there were no significant differences 
between patients who did and did not complete the PRO booklet (Table S10). There 
was no evidence of any differences between treatment technique groups for EPIC or 
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Vaizey summary scores (Table 2), with no suggestion of a worsening of Vaizey 
score with increased dose volume or dose surface at any dose level (Table S11). 
Median DVH and DSH values were calculated for patients whose EPIC bowel and 
urinary scores were below and above the threshold level previously defined (Table 
S3). There was a trend that patients whose score were below the cut-point had 
higher dose volume or surface levels (Figure S1).  
 
Thirty-three patients had biochemical/clinical failure reported (4, 20 and 9 in no 
IGRT, IGRT-S and IGRT-R groups respectively) (Table S12 and Figure S2). Five-
year biochemical/clinical failure free survival was 91.1 (95% CI 77.9-96.6), 85.2 
(95%CI 77.7-90.3) and 93.1 (95%CI 86.1-96.7) for no IGRT, IGRT-S and IGRT-R 
groups respectively. Fourteen patients had recommenced androgen deprivation 
therapy, nine had local recurrence, seven had lymph node/pelvic recurrence and 
seven had distant recurrence. Twenty-seven patients had died, three from prostate 
cancer, twenty-three from other reasons and one unknown.  
 
Discussion  
We have demonstrated that implementation of IGRT was feasible in a multi-centre 
trial in the UK. Recruitment of patients was swift and completed within one year. 
Accrual peaked at 45 patient/month, with 16 radiotherapy centres participating. 
Subsequently IGRT has become part of the national guidelines recommended 
treatment pathway. This emphasises the importance of clinical trials as a vehicle to 
introduce advanced radiotherapy technology. Limitations of this substudy include its 
relatively small size, uneven randomisation between treatment technique groups and 
PRO assessment at a single time point. Yet, to our knowledge, this is the only 
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randomised prospective study evaluating no-IGRT, IGRT and treatment margins 
using the same planning techniques. 
We found minimal toxicity associated with insertion of fiducial markers. Dosimetric 
assessments showed that reduced margins in the IGRT-R group resulted in rectal 
and bladder volumes receiving 5-65Gy being significantly lower (<0.0001) than using 
standard margins, this was also seen for surface dose. The mean dose to rectal 
surface in the IGRT-S group was  33.9(±5.1)Gy and similar to that previously 
reported of 34.4(±7.2)Gy using IG-IMRT28 despite differences in dose prescription 
and margining techniques. As expected, mean dose to rectum in the IGRT-R group 
was significantly lower at 28.9(±4.2)Gy. Similarly, mean dose to bladder surface was 
26.6(±9.2)Gy / 20.5(±6.6)Gy for IGRT-S / IGRT-R groups respectively, both lower 
than previously reported (33.1 ± 10.9Gy).28 Late GI toxicity was consistently reported 
less often using the three clinician based scores in the IGRT-R group. However, the 
improved rectal dosimetry did not translate into a statistically significant benefit in 
acute or late GI toxicity, with the possible exception of grade ≥2 RMH GI side-effects. 
This perhaps unexpected result may relate to the low level of side-effects seen in all 
randomised dose/fractionation groups in the main CHHiP trial which used strict 
normal tissue dose constraints and a SIB technique limiting dose to the seminal 
vesicles.10 The lack of reduction in acute and late GU side effects may relate to 
similar doses to the urethra in all treatment technique groups. It may be the 
combination of dose/volume/fractionation employed in the trial has reached a plateau 
for radiotherapy side effects and other patient29, radiogenomic30 or microbiota31 
related factors become more important in determining residual symptoms. We 
believe it imprudent to extrapolate to treatments using higher doses, treating larger 
target volumes or using more extreme forms of hypofractionation where the clinical 
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benefits of IGRT-R might be more apparent. Previous non-randomised studies 
comparing patient cohorts treated with IG-IMRT and 3D-CFRT28,29 have suggested 
improvements in grade≥2 GU or GI side-effects using IGRT but are compromised by 
differences in planning and delivery techniques as well as differing dose constraints. 
Two randomised trials have evaluated daily versus weekly image guided 
radiotherapy. Tondel et al. reported no difference in acute patient reported 
outcomes, despite dosimetric advantages seen with daily CBCT and reduced 
margins, their late toxicity results are awaited.32 A further study by de Crevoisier et 
al. showed no statistically significant difference in recurrence free survival, with also 
no difference in acute toxicity.33 A statistically significant difference in late rectal 
toxicity and improvement in biochemical recurrence was reported, albeit with a short 
median follow up of 4.1 years. We found no evidence to suggest that IGRT was 
associated with a reduction in disease control. IGRT may increase accuracy and 
reduce the chance of underdosage in the target volume, alternatively however it is 
possible that the reduced margins might lower inadvertent dose outside the prostate 
which has been suggested as a cause of treatment failure.34  
The IGRT experience gained within this study has facilitated development of a new 
national trial PIVOTALboost (CRUK/16/018) in which all patients receive IG-IMRT 
and are randomised to receive pelvic lymph node IMRT or MR-directed dominant 
lesion boosts using hypofractionated schedules as in the CHHiP study. 
 
We have shown it is feasible to introduce prostate IGRT in a national randomised 
trial and that reduced margins translate into dosimetric benefits. Overall side effect 
profiles were low with and without IGRT in the CHHiP trial and this substudy.  
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Figure legends 
Figure 1: CONSORT diagram 
Figure 2: Boxplots illustrating dose volume and dose surface histograms, the 
calculated volume and surface percentages for rectum (A) and bladder (B) normal 
tissues by IGRT group and dose 
KEY: All doses are equivalent dose in 2Gy fractions. Red boxplots represent patients 
treated with no IGRT, green boxplots are those patients treated with IGRT standard 
margins and blue boxplots are those patients treated with IGRT reduced margins. 
Figure 3 – Acute RTOG bowel (A) and bladder (B) toxicity by timepoint and IGRT 
group. Distribution of grade and prevalence 
Figure 4 – Bowel (A) and bladder (B) toxicity assessed using RTOG, RMH and 
LENTSOM by timepoint and IGRT group. Distribution and cumulative proportion with 
grade≥1 and grade≥2 radiation induced late toxicity. 
KEY: For cumulative proportion plots: red=No IGRT, Green= IGRT-S, Blue=IGRT-R. 
Solid lines indicated grade≥1 events and dashed lines indicate grade≥2 events 
NB. Late toxicity data have been included in stacked bar charts if they were reported 
within 6 weeks of the 6 month visit, within 3 months of the 12-24 month visits and 
within 6 months of the 36 and 48 month visits.  
 
Table 1: Baseline characteristics by treatment group (n=293) 
Table 2: Bowel and urinary domain scores using EPIC questionnaire and scoring 
system by treatment group at a median follow-up of 50.3 months (IQR: 47.8-52.0 
months) 
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Supplementary material (online only) 
Table S1: Margin definition and target isodose levels prescriptive to the planning 
Table S2: Normal tissue dose constraints 
Table S3: EPIC bowel domain mean and standard deviation scores from the CHHiP 
QoL substudy and the calculated threshold dose 
Table S4: Treatment planning data 
Table S5: P-values for statistical comparison of dose volume and dose surface 
histograms for No IGRT vs IGRT-S and IGRT-S vs IGRT-R. All doses are in 
equivalent dose in 2Gy fractions. 
Table S6: Descriptive statistics given by IGRT treatment allocation for the rectum 
constraints 
Table S7: Descriptive statistics given by IGRT treatment allocation for the bladder 
constraints 
Table S8: Number and proportion with RTOG grade>=2 toxicity at 2 years with 95% 
confidence intervals - by treatment group and randomisation strategy 
Table S9: Hazard ratios and cumulative proportion with G1+, G2+ and G3+ bowel 
and bladder toxicity at 2 years assessed by RTOG, RMH and LENTSOM scoring 
systems 
Table S10: Baseline characteristics for PRO responders and non-responders 
Table S11: Percentage volume and surface receiving each dose level according to 
Vaizey scores categorised as tertiles (Ter1=Vaizey score 0-2; Ter2=Vaizey total 3-5; 
Ter3=Vaizey score 6-20). All doses are equivalent dose in 2Gy fractions. 
Table S12: Efficacy data by IGRT substudy group 
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Figure S1: Boxplots showing along the top row the dose volume histograms for 
patients whose EPIC bowel (A) and urinary (B) domain scores were above or below 
the defined thresholds. The dose surface histograms are shown along the bottom 
row for those patients whose EPIC bowel (A) and urinary (B) domain scores were 
above or below the defined thresholds. All doses are equivalent dose in 2Gy 
fractions. 
Figure S2: Kaplan Meier for biochemical/clinical failure free survival by IGRT 
substudy group  
Radiotherapy Quality Assurance in the CHHiP IGRT substudy 
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 Table 1: Baseline characteristics by treatment group (n=293) 
  
No IGRT 
N=48 
n (%) 
IGRT - S 
N=137 
n (%) 
IGRT - R 
N=108 
n (%) 
Randomisation option 
No IGRT v IGRT-S v IGRT-R 
No IGRT v IGRT-S 
IGRT-S v IGRT-R 
 
16 (33) 
32 (67) 
- 
 
13 (9) 
32 (23) 
92 (67) 
 
13 (12) 
- 
95 (88) 
Age at registration (years)    
Median (IQR) 71 (66-73) 72 (66-75) 71 (67-75) 
Range 57-80 53-82 54-80 
Time from histological 
confirmation of prostate 
cancer to randomisation (wks) 
Median (IQR) 
Range 
16 (13-25) 
6-350 
17 (13-27) 
3-278 
18 (13-25) 
4-265 
T stage (clinical assessment)    
T1 16 (33) 46 (34) 43 (40) 
T2 27 (56) 83 (61) 56 (52) 
T3 5 (10) 8 (6) 9 (8) 
Grading group(Gleason score)    
1 (3+3) 13 (27) 42 (31) 31 (29) 
2 (3+4) 30 (63) 61 (45) 55 (51) 
3 (4+3) 
4 (4+4, 3+5, 5+3) 
4 (8) 
1 (2) 
32 (23) 
2 (1) 
19 (18) 
3 (3) 
PSA (pre-hormone treatment) 
(ng/ml)    
Median (IQR) 9.5 (6.8-15.2) 9.7 (6.9-12.5) 8.3 (6.9-11.4) 
Mean (SD) 11.1 (4.9) 10.3 (4.6) 9.1 (3.8) 
PSA (ng/ml)    
0.0-4.99 2 (4) 13 (10) 12 (11) 
5.0-9.99 23 (48) 57 (42) 60 (56) 
10.0-19.99 20 (42) 65 (48) 36 (33) 
20.0-49.99 3 (6) 2 (2) 0 
NCCN Risk group    
Low 2 (4) 16 (12) 17 (16) 
Medium 38 (79) 109 (80) 80 (74) 
High 8 (17) 12 (9) 11 (10) 
CHHiP treatment allocation 
74Gy/37Fr 
60Gy/20Fr 
57Gy/19Fr 
18 (38) 
15 (31) 
15 (31) 
44 (32) 
48 (35) 
45 (33) 
33 (31) 
37 (34) 
38 (35) 
Table 1
 
 Table 2: Bowel and urinary domain scores using EPIC questionnaire and scoring system by treatment 
group at a median follow-up of 50.3 months (IQR: 47.8-52.0 months) 
 
 
No IGRT IGRT-S IGRT-R 
 No. of pts 
with data 
Median 
(IQR) 
No. of pts  
With data 
Median (IQR) No. of pts  
with data 
Median (IQR) 
Bowel function 29  96.4  
(89.3-100) 
89  92.9  
(85.7-96.4) 
75  96.4  
(85.7-100) 
P-value   0.2101  0.5002 
Bowel bother 29  96.4  
(87.5-100) 
83 92.9 
(85.7-100) 
74 92.9  
(85.7-100) 
P-value   0.4751  0.9092 
Bowel summary 29  94.6 
(89.3-98.2) 
84 94.6  
(87.5-96.4) 
74 92.9  
(87.5-98.2) 
P-value   0.2181  0.5862 
Urinary function 28  97.5  
(92.2-100) 
87  100  
(89.2-100) 
75  95  
(88.4-100) 
P-value   0.9411  0.4092 
Urinary bother 28  82.1  
(74.1-93.8) 
80  85.7  
(71.4-92.9) 
70  85.7  
(75.9-92.9) 
P-value   0.9471  0.4562 
Urinary incontinence 27  100  
(82.4-100) 
79  93.8  
(85.5-100) 
71  93.8  
(79.3-100) 
P-value   0.9851  0.4732 
Irritative/Obstructive 28  88.4 
(78.6-96.0) 
79  89.3  
(80.7-92.9) 
70  89.3  
(85.7-96.4) 
P-value   0.8611  0.4542 
Urinary summary 27  88.9  
(80.6-96.9) 
79  88.9  
(78.7-95.8) 
71  89.6  
(84-94.8) 
P-value   0.9451  0.7332 
Vaizey total score 27 4 (1-5.5) 84 4 (1-7) 72 4 (1-6) 
   0.0481  0.8212 
1 Comparison of No IGRT and IGRT-S groups 
2 Comparison of IGRT-S and IGRT-R groups 
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